We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Understanding Cancer Immunoediting Will Aid Vaccine Development

By LabMedica International staff writers
Posted on 29 Feb 2012
The body’s immune system employs the process of cancer immunoediting to eliminate tumor cells bearing highly antigenic mutant proteins and to suppress growth of those cancer cells that lack these antigens.

Cancer immunoediting, the process by which the immune system controls tumor outgrowth and shapes tumor immunogenicity, is comprised of three phases: elimination, equilibrium, and escape. More...
Although many immune components that participate in this process are known, its underlying mechanisms remain poorly defined. To understand better the molecular basis that drives immunoediting, investigators at Washington University School of Medicine (St. Louis, MO, USA) induced the formation of sarcomas in a line of immunocompromised mice.

The investigators then used massive parallel DNA sequencing to characterize mutations expressed on the sarcoma cells, which were phenotypically similar to unedited primary tumors growing in immunocompetent hosts.

Results published in the February 16, 2012, issue of the journal Nature revealed that the genome of the sarcoma cells contained 3,743 mutations. Using class I prediction algorithms, they identified the protein produced by the mutant spectrin-beta2 gene as a potential rejection antigen of the sarcoma and validated this prediction by conventional antigen expression cloning and detection. They also demonstrated that cancer immunoediting occurred via a T-cell-dependent immunoselection process that promoted outgrowth of preexisting tumor cell clones lacking highly antigenic mutant spectrin-beta2 and other potential strong antigens.

“The idea would be to make a vaccine that helps the immune system recognize and attack six or seven of these mutated proteins in a cancer,” said senior author Dr. Robert Schreiber, professor of pathology and immunology at Washington University School of Medicine. “Therapeutically, that could be very helpful.”

“Many of the cancer genome projects now under way are looking for the “driver” mutations, or the mutations that cause the cancers,” said Dr. Schreiber. “Our results suggest there may be additional information in the sequencing data that can help us make the immune system attack cancers. Until very recently, this work would have been impractical because of the costs involved, but the technology has improved and prices have come down, and now it is possible to obtain this genetic information for a few thousand dollars instead of a million.”

Related Links:

Washington University School of Medicine



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Immunofluorescence Analyzer
IFA System
New
Rapid Sepsis Test
SeptiCyte RAPID
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Mycobacterium tuberculosis bacteria seen with a scanning electron microscope (Credit: CDC PHIL)

Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection

Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.